Coinfection by human immunodeficiency virus and hepatitis C virus: Noninvasive assessment and staging of fibrosis

Current Opinion in Infectious Diseases

Volumn 25, Issue 5, 2012, Pages 564-569

  Resino, Salvador ^a   Sánchez Conde, Matilde ^b   Berenguer, Juan ^b,c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

AIDS; chronic hepatitis C; fibrosis; serum biomarkers; transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER;

CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; ELASTOGRAPHY; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LYMPHOCYTE COUNT; MIXED INFECTION; NON INVASIVE PROCEDURE; NONHUMAN; PORTAL HYPERTENSION; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REVIEW;

ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; COINFECTION; ELASTICITY IMAGING TECHNIQUES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; PREDICTIVE VALUE OF TESTS;

EID: 84865864055     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835635df     Document Type: Review

References (46)

1. Lopez-Dieguez M, Montes ML, Pascual-Pareja JF, et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS 2011; 25:899-904.
2. Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50:1056-1063.
3. Lopez-Dieguez M, Montes M, Pascual-Pareja J, et al. The natural history of liver cirrhosis in HIV-HCV coinfected patients. AIDS 2011; 25:899-904.
4. Lo Re Iii V, Kostman JR, Amorosa VK. Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 2008; 12:587-609.
5. Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIVinfected patients. Clin Infect Dis 2008; 47:94-101.
6. Calvaruso V, Craxì A. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012; 32 (Suppl 1):2-8.
7. Bonacini M. Diagnosis and management of cirrhosis in coinfected patients. J Acquir Immune Defic Syndr 2007; 45 (Suppl 2):S38-S46.
8. Castera L, Pinzani M. Noninvasive assessment of liver fibrosis: are we ready? Lancet 2010; 375:1419-1420.
9. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
10. Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? Liver Int 2011; 31 (Suppl 1):13-17.
11. Castera L. Invasive and noninvasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol 2011; 25:291-303.
12. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53:325-335.
13. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009; 50:36-41.
14. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
15. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53:726-736.
16. Sebastiani G, Castera L, Halfon P, et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of noninvasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther 2011; 34:1202-1216.
17. Resino S, Asensio C, Bellon JM, et al. Diagnostic accuracy of the APRI, FIB-4, and the Forns index for predicting liver fibrosis in HIV/HCV-coinfected patients: a validation study. J Infect 2011; 63:402-405.
18. Macias J, Gonzalez J, Ortega E, et al. Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice. HIV Med 2010; 11:439-447.
19. Loko MA, Castera L, Dabis F, et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol 2008; 103: 1973-1980.
20. Cacoub P, Carrat F, Bedossa P, et al. Comparison of noninvasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study: ANRS HC02. J Hepatol 2008; 48:765-773.
21. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36:986-992.
22. Singal AG, Thomassen LV, Gretch DR, Shuhart MC. Use of the AST to platelet ratio index in HCV/HIV co-infected patients. Aliment Pharmacol Ther 2011; 33:566-577.
23. Schiavon LL, Narciso-Schiavon JL, Carvalho-Filho RJ, et al. Impact of CD4+ T-cell count on the performance of noninvasive fibrosis markers in HIV-HCV patients. Aliment Pharmacol Ther 2011; 33:1173-1174.
24. Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci 2011; 56:3038-3044.
25. Resino S, Seoane JA, Bellon JM, et al. An artificial neural network improves the noninvasive diagnosis of significant fibrosis in HIV/HCV coinfected patients. J Infect 2011; 62:77-86.
26. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-1325.
27. Berenguer J, Bellon JM, Miralles P, et al. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 2007; 14:859-869.
28. Calvaruso V, Maimone S, Gatt A, et al. Coagulation and fibrosis in chronic liver disease. Gut 2008; 57:1722-1727.
29. Connoy A, Turner J, Nunez M. Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use. AIDS Res Hum Retroviruses 2011; 27:719-725.
30. Resino S, Bellon JM, Asensio C, et al. Can serum hyaluronic acid replace simple noninvasive indexes to predict liver fibrosis in HIV/hepatitis C coinfected patients? BMC Infect Dis 2010; 10:244.
31. Resino S, Micheloud D, Miralles P, et al. Diagnosis of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new noninvasive index: the HGM-3 index. HIV Med 2010; 11:64-73.
32. Macias J, Mira J, Gilabert I, et al. Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitisCvirus-coinfected patients. HIVMed 2011; 12:14-21.
33. Cales P, Halfon P, Batisse D, et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol 2010; 53:238-244.
34. Cales P, Boursier J, Bertrais S, et al. Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem 2010; 43:1315-1322.
35. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134:960-974.
36. Neukam K, Recio E, Camacho A, et al. Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry. Eur J Gastroenterol Hepatol 2010; 22:801-807.
37. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44:214-219.
38. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55:403-408.
39. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53:1013-1021.
40. Sánchez-Conde M, Montes-Ramirez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010; 17:280-286.
41. Sánchez-Conde M, Montes Ramirez ML, Bellon Cano JM, et al. Impact of liver steatosis on the correlation between liver stiffness and fibrosis measured by transient elastography in patients coinfected with human immunodeficiency virus and hepatitis C virus. J Viral Hepat 2011; 18:e278-e283.
42. Lawson A, Hagan S, Rye K, et al. The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol 2007; 47:37-45.
43. Bosch J, Navasa M, Garcia-Pagan JC, et al. Portal hypertension. Med Clin North Am 1989; 73:931-953.
44. Sánchez-Conde M, Miralles P, Bellon JM, et al. Use of transient elastography (FibroScan(R)) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients. J Viral Hepat 2011; 18:685-691.
45. Castera L, Le Bail B, Roudot-Thoraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and noninvasive scores. J Hepatol 2009; 50:59-68.
46. Pineda JA, Recio E, Camacho A, et al. Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis. J Acquir Immune Defic Syndr 2009; 51:445-449.